降压降脂联合治疗对原发性高血压患者炎性标记物的影响

The effect of combination of antihypertensive and lipid lowering therapy on patients with primary hypertension

目的探讨降压降脂联合治疗对原发性高血压患者炎性标记物的影响。方法入选2009年12月至2011年12月在佛山南海区第六人民医院就诊并住院治疗的原发性轻中度高血压患者240例，随机分为降压组（120例）和联合组（120例）。降压组患者只给予单纯降压治疗；联合组患者在降压基础上给予降脂治疗，瑞舒伐他汀5mg，每晚一次。比较两组患者治疗前、后炎性因子水平。结果治疗后两组患者血压和炎性因子水平均下降，与治疗前相比差异有统计学意义（P〈0．05）；治疗后联合组炎性因子水平比降压组下降更明显，且差异有统计学意义（P〈0．05）。结论在降压基础上增加降脂治疗，能有效降低高血压患者炎性因子水平，改善患者预后。

Objective To investigate the effect of combination of antihypertensive and lipid lowering ther- apy on patients with primary hypertension. Methods 240 primary hypertension patients from our hospital were en- rolled from December 2009 to December 2011, and divided into anti-hypertensive group （n=120） and combination group （n=120）, anti-hypertensive group patients were given antihypertensive medicine, combination group were given antihypertensive and lipid lowering medication of rosuvastatin 5 mg per night, the level of inflammatory factors were examined in two groups. Results Blood pressure and inflammatory factors level were lowered in both groups, and more significantly in combination group （P〈0.05 in both groups）. Conclusion Antihypertensive combined with lipid lowering therapy can further lower inflammatory factors in patients with primary hypertension and improve outcomes.